Prevalence and Characteristics of Metabolic Syndrome in Schizophrenic Inpatients

Yoon, Bo-Hyun; Bae, Ahn; Bahk, Won‐Myong

doi:10.1016/s0920-9964(08)70539-5

Cited by 4 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Though a few researchers have studied the change in prevalence rates over time, largely the estimates have been cross-sectional. Amongst the cross sectional studies, as depicted in Table 1,[101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899] most studies have evaluated the patients who are already on treatment and only a few have assessed the prevalence of MetS in drug naive population. Most of the studies have ...…”

Section: Prevalence Of Metabolic Syndrome In Schizophreniamentioning

confidence: 99%

“…[5296] Another clinical variable inconclusively associated with MetS is age of onset with Yaziki et al . [95] demonstrating the prevalence to be higher in those with late age at onset of illness, while Kaya et al .…”

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

“…Some studies have reported that MetS is more common in females,[ 16 44 64 73 87 88 89 ] while others have reported no gender differences in the prevalence rates of MetS[ 10 15 18 31 41 54 82 ] and only a few studies have reported higher prevalence in males. [ 96 111 ] Occasional studies have reported association of MetS with higher education level,[ 35 98 ] urban background,[ 38 ] employed status,[ 37 38 ] and marital status. [ 11 37 ]…”

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

“…While a longer duration of illness has been demonstrated to be associated with higher prevalence of MetS in some of the studies,[ 10 19 36 39 50 87 ] some studies have shown no association of MetS and duration of illness. [ 52 96 ] Another clinical variable inconclusively associated with MetS is age of onset with Yaziki et al . [ 95 ] demonstrating the prevalence to be higher in those with late age at onset of illness, while Kaya et al .…”

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

“…Studies that have followed up drug naïve patients after institution of antipsychotics have demonstrated increment of prevalence rate ranging from 7% to 42% over a period ranging from 3 months to 4 years. Though many authors have failed to demonstrate an association of MetS with a specific atypical antipsychotic,[ 34 38 39 43 51 82 96 ] or the mean chlorpromazine (CPZ) dose,[ 50 ] still there is some evidence to suggest that atypical antipsychotics do differ in their propensity to cause metabolic syndrome. Highest association was seen with clozapine and olanzapine in cross-sectional studies.…”

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

See 4 more Smart Citations

Metabolic Syndrome in Schizophrenia

Malhotra¹,

Grover²,

Chakrabarti³

et al. 2013

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

To review the data with respect to prevalence of metabolic syndrome (MetS) and its correlates in schizophrenia. For this review, electronic search engines PUBMED, Sciencedirect, and Google Scholar were used. Available data suggests that most of the studies have been of cross-sectional design. Prevalence rates of MetS have varied from 11% to 69% in medicated patients, and 4-26% in drug naive patients in cross-sectional evaluations. Longitudinal studies have shown the prevalence rates to range from 0% to 14% at the baseline in drug naive patients, which increase to as high as 52.4% by 3 months of antipsychotic medication treatment. The prevalence rates of MetS in patients with schizophrenia are much higher than that seen in general population or healthy controls. Though there is no causal association with any demographic or clinical variables, the risk increases with increase in age. Among antipsychotics, there seems to be an association between MetS and atypical antipsychotics like clozapine and olanzapine. Therefore, the psychiatrists should be more vigilant regarding the presence of MetS in these high risk groups. Research on biological correlates of MetS in schizophrenia is still in its primitive stage, however, these is some evidence to suggest an association of MetS with adiponectin levels, hematological indices, methylenetetrahydrofolate reductase (MTHFR) and Alpha-1A adrenergic receptor (ADRA1A) gene. These areas hold promise, and targeting these with appropriate interventions may help us to prevent the occurrence of MetS in patients with schizophrenia in future.

show abstract

Section: Prevalence Of Metabolic Syndrome In Schizophreniamentioning

confidence: 99%

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

Section: Predictors Of Mets In Schizophreniamentioning

confidence: 99%

See 3 more Smart Citations

Metabolic Syndrome in Schizophrenia

Malhotra¹,

Grover²,

Chakrabarti³

et al. 2013

Indian Journal of Psychological Medicine

View full text Add to dashboard Cite

show abstract

Prevalence of metabolic syndrome in Iranian patients with schizophrenia: A systematic review and meta-analysis

Shojaeimotlagh

Hashiehbaf²,

Karami

et al. 2019

Diabetes & Metabolic Syndrome: Clinical Research & Revi

View full text Add to dashboard Cite

Metabolic syndrome in patients with Schizophrenia: Relationship with socio-demographic & clinical variables

Sattar¹,

Raj²,

K³

2020

Telangana J Psychiatry

View full text Add to dashboard Cite

Background: Schizophrenia is an enduring severe mental illness with significant morbidity and early excess mortality. Metabolic syndrome (MetS) is a construct that aids psychiatrist to understand this constellation of risk factors leading to premature mortality. The current study was carried out with an aim to understand the association of metabolic syndrome in patients with schizophrenia and also to ascertain its relationship with socio-demographic & clinical variables. Materials and Methods: A cross sectional study was undertaken in patients suffering from Schizophrenia (F20) as per International Classification of Diseases (ICD-10. A total of one-hundred patients were selected by purposive random sampling after obtaining a written informed consent. A predesigned proforma was used to obtain the information regarding the sociodemographic variables, drug intake, anthropometric values and metabolic parameters. Metabolic syndrome was diagnosed as per the International Diabetes Federation-2006 criteria. The data obtained was analysed using statistical package for social services (SPSS 20). Results: The association of metabolic syndrome in schizophrenia in the current study was 42%. The individual metabolic parameters were found to be higher in the MetS group than the non-MetS group (p=0.001). Majority of the schizophrenia patients with MetS were older (59.5% vs 44.8%; 31-50 years of age) and females (52.4% vs 36.2%; p=0.107) compared to those without MetS. Most of them were married (85.7% vs 56.9%; p=0.006), from urban areas (45.2% vs 19%; p=0.005), had lower educational qualification (p=0.01) in comparison to the non-MetS group. The MetS group had longer mean duration of schizophrenia (9.64±8.1 years vs 3.76±2.29 years), more hospitalizations (66.7% vs 53.4%; p=0.02) and higher medical comorbidity (diabetes-7.1% vs nil, hypertension-9.5% vs 1.7% and hypothyroidism-7.1% vs nil; p=0.006). With respect to psychotropic drugs usage; the use of Olanzapine (69% vs 46.6%; p=0.025), longer duration of treatment with Olanzapine (26.31 ± 33.9 months vs 8.98 ± 12.3; p=0.001) and Amisulpride (11.0 ± 21.68 months vs 3.48 ± 9.9; p=0.022) were significantly associated with MetS group than the group without MetS. On the contrary, the non-MetS group had more patients receiving risperidone (58.6%) than the MetS group. Conclusion: The study shows that the association of metabolic syndrome in schizophrenia patients is significantly in higher percentage and thereby underlines the importance of early detection and treatment of both the disorders simultaneously.

show abstract

Prevalence and Characteristics of Metabolic Syndrome in Schizophrenic Inpatients

Cited by 4 publications

References 0 publications

Metabolic Syndrome in Schizophrenia

Metabolic Syndrome in Schizophrenia

Prevalence of metabolic syndrome in Iranian patients with schizophrenia: A systematic review and meta-analysis

Metabolic syndrome in patients with Schizophrenia: Relationship with socio-demographic & clinical variables

Contact Info

Product

Resources

About